Your SlideShare is downloading. ×
Abbott
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Abbott

393
views

Published on

Published in: Business, Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
393
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
18
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Abbott
  • 2. Dr. Wallace C. Abbott 1888. Begins manufacturing dosimetric granules 1894 Dr. Abbott acquires and becomes editor of The Alkaloidal Clinic 1900 Officially incorporated as the Abbott Alkaloidal Company 1906 To reach more physicians, Dr. Abbott establishes the company’s sales force
  • 3. History • 1900 Modest Origin • 1910 Expanded to oNew York (US) oSeattle (US) oSan Fransico (US) oToronto (Canada) • 1915 changed name Abbott Laboratories • 1929 about 120 facilities world wide • Major player
  • 4. Innovator Products • Chlorazene 1916 • Butyn 1923 • Nembutal 1930 • Pantothal 1936 • Halazone 1942 • Tridione • Surbex 1945 • Disposable I.V. Set • Aminosol 1947 • Selsun Susp. 1951 • Erythrocin 1952 • Hytrin 1987
  • 5. Acquisitions... Year Acquisition Price Strategic Fit 2001 Knoll (a unit of BASF) $6.9B (Cash) Acquired the rights to Humira 2004 Therasense $1.1B (Cash Acquired products for diabetes treatment 2005 Guidant’s vascular unit $5.5B (Cash) Acquired several vascular products 2006 Kos Pharmaceutical $3.7B (Cash) Acquired cholesterol treatments 2009 Advanced Medical Optics $2.8B (Cash) Acquired #1 maker of LASIK surgical devices 2009 Solvay’s drug unit $6.6B (Cash) Expanded pharmaceutical portfolio 2010 Piramel Healthcare $3.8B (Cash) Expanded pharmaceutical portfolio abroad
  • 6. Business in 2011 • Record revenues of 38.9 Billions $ • 59 % of income came from outside US Abbott Johnson & Johonson Pfizer Merk & co. Eli lilly & Co. 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% Net Profit Margin ROE
  • 7. Drug development cost in $ 0 200 400 600 800 1000 1200 1400 1975 1987 2001 2006 Abbott Abbott
  • 8. • Oct 2011 Abbott plans to separate in two companies Abbott Laboratories Abbot Abb Vie
  • 9. Idea of Global Citizenship •Supporting patient and consumers oEducating Patient and professionals oEnsuring Manufacturing Quality oResponsible sales and marketing practices •Safeguarding Environment o Economic oEnvironmental oSocial Wellbeing Scientific Expertise Business Acumen Recourses Employees
  • 10. Future Steps • Research & Development o30 Compounds in development o12 Nutritional products and Medical devices • Partnering with oAcademics oGovernment oPrivate companies To Advance personalise medicine, to improve healthcare technology and to fight neglected tropical diseases
  • 11. Products